AUTHORS
Zidan Feng, N/A, Kejia Hu2, Dongrui Wang3, Yongxian HU, MD4, He Huang, MD, PhD5
AFFILIATIONS
1 Liangzhu Laboratory, Hangzhou, Zhejiang, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
2 Liangzhu Laboratory, Hangzhou, Zhejiang, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
3 Liangzhu Laboratory, Hangzhou, Zhejiang, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
4 Liangzhu Laboratory, Hangzhou, Zhejiang, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
5 Liangzhu Laboratory, Hangzhou, Zhejiang, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
ABSTRACT
Background: Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized outcomes for relapsed/refractory multiple myeloma (RRMM), yet post-treatment relapse remains a critical challenge. The gut microbiota regulates systemic immune homeostasis, and emerging evidence suggests that antibiotic-induced dysbiosis may adversely affect therapeutic outcomes.
Methods: Study patients were primarily enrolled in clinical trials ChiCTR1800017404 and NCT05430945 and followed from July 30, 2018, to September 27, 2023. To specifically investigate subsequent disease progression, the analysis was restricted to patients who achieved an initial objective response and met sequencing quality-control criteria, yielding a final cohort of 56 patients. Antibiotic exposure was assessed according to antibiotic use during the prespecified interval from the Initial stage (I-stage) to the Evolution stage (E-stage) after CAR-T cell infusion. Gut microbiome profiling was performed in 56 patients, with fecal and serum metabolomic analyses in 22 and 23 patients, respectively. Clinical and multi-omics features were analyzed in relation to antibiotic exposure and subsequent disease progression.
Results: Among 56 evaluable patients, 28 (50.0%) were aged >60 years and 28 (50.0%) were male. At baseline, 47 (83.93%) had Durie-Salmon stage III disease, 34 (60.71%) had high-risk cytogenetics, and 27 (48.21%) had extramedullary disease. Patients had received a mean of 3.41 prior lines of therapy (range, 2–10), and 20 (35.71%) had undergone prior autologous stem cell transplantation. During follow-up, 25 patients experienced disease progression, whereas 31 remained free from progression. Post-infusion exposure to piperacillin-tazobactam was associated with poorer clinical outcomes. Metagenomic analysis identified a non-progression-associated microbial signature termed PRSN. The PRSN signature comprised Pseudoramibacter alactolyticus, 4 Rothia species, Streptomyces lividans, and 2 Neisseria species. These taxa were associated with a Streptococcus pyogenes PBP2x resistome feature linked to reduced β-lactam susceptibility. Furthermore, integrated metabolomic analyses implicated sphingolipid metabolism as a major metabolic pathway associated with these microbiome alterations and disease progression.
Conclusions: Post-infusion piperacillin-tazobactam exposure was associated with poorer clinical outcomes and gut microbial alterations in patients with RRMM receiving CAR-T cell therapy. The PRSN signature, PBP2x-associated resistome features, and sphingolipid-related metabolic alterations suggest a potential microbiome-metabolite link to post-CAR-T disease progression and underscore the importance of antibiotic stewardship.
DISCLOSURES
Zidan Feng, N/A: No relevant conflicts of interest to declare.